Clinically significant localised prostate cancer: deciding what will provide the best clinical outcomes

Woo, Henry H; Teh, Amy

doi:10.5694/mja2.50983

Topics

Prostate cancer specialists working in collegiate, multidisciplinary teams are most likely to provide the best outcomes for patients

In the absence of formal comparative studies, there is no real evidence that the outcomes of surgery or radiotherapy for patients with localised prostate cancer differ significantly. However, most men in Australia with clinically significant localised prostate cancer undergo surgery rather than radiotherapy.

1 Sydney Adventist Hospital Clinical School, University of Sydney, Sydney, NSW
2 Chris O’Brien Lifehouse, Sydney, NSW
3 Icon Cancer Centre, Sydney, NSW

Correspondence: henry.woo@sydney.edu.au

Competing interests:

Henry Woo has received speaker’s and advisory board fees from Astellas, Janssen, and Boston Scientific.

1. Yap ML, O’Connell DL, Goldsbury DE, et al. Patterns of care for men with prostate cancer: the 45 and Up Study. Med J Aust 2021; 214: 271–278.
2. Mottet N, van den Bergh RCN, Briers E, et al. EAU‐EANM-ESTRO‐ESUR-SIOG guidelines on prostate cancer, 2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2020; 79: 243–262.
3. te Marvelde L, Milne RL, Hornby CJ, et al. Differences in treatment choices for localised prostate cancer diagnosed in private and public health services. Med J Aust 2020; 213: 411–417. https://www.mja.com.au/journal/2020/213/9/differences-treatment-choices-localised-prostate-cancer-diagnosed-private-and
4. Australian Department of Health. Medicare Benefits Schedule, note TN.8.161. Urology oncology: prostatectomy. (items 37210, 37211, 37213 and 37214). http://www9.health.gov.au/mbs/fullDisplay.cfm?type=note&qt=NoteID&q=TN.8.161 (viewed Jan 2021).
5. Mazariego CG, Egger S, King MT, et al. Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. BMJ 2020; 371: m3503.
6. Matta R, Chapple CR, Fisch M, et al. Pelvic complications after prostate cancer radiation therapy and their management: an international collaborative narrative review. Eur Urol 2019; 75: 464–476.
7. Kneebone A, Fraser‐Browne C, Duchesne GM, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non‐inferiority trial. Lancet Oncol 2020; 21: 1331–1340.
8. Valle LF, Lehrer EJ, Markovic D, et al. A systematic review and meta‐analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol 2020; S0302‐2838(20)30874‐5 [online ahead of print].
9. Yuh B, Ruel N, Muldrew S, et al. Outcomes of salvage robot‐assisted prostatectomy. BJU Int 2014; 113: 769–776.
10. Australian Department of Health. Overview: key Medicare safety net arrangements. Updated 20 Dec 2019. https://www1.health.gov.au/internet/main/publishing.nsf/Content/EMSN-overview-key-medicare-safety-net-arrangements (viewed Jan 2021).
11. Evans SM, Nag N, Roder D, et al. Development of an international prostate cancer outcomes registry. BJU Int 2016; 117 (Suppl 4): 60–67.

Online responses are no longer available. Please refer to our instructions for authors page for more information.